Insider Selling: Lantheus Holdings Inc (NASDAQ:LNTH) Director Sells $142,050.00 in Stock

Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $28.41, for a total value of $142,050.00. Following the sale, the director now directly owns 32,467 shares in the company, valued at $922,387.47. The transaction was disclosed in a filing with the SEC, which is available at this link.

LNTH stock opened at $28.72 on Monday. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of 30.55, a P/E/G ratio of 2.16 and a beta of 1.49. Lantheus Holdings Inc has a 12-month low of $12.59 and a 12-month high of $29.80. The firm’s 50 day moving average price is $26.08.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The firm had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. On average, equities research analysts forecast that Lantheus Holdings Inc will post 1.11 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. increased its position in Lantheus by 4.0% in the fourth quarter. Victory Capital Management Inc. now owns 16,426 shares of the medical equipment provider’s stock worth $257,000 after buying an additional 639 shares during the period. Campbell & CO Investment Adviser LLC acquired a new stake in Lantheus in the first quarter worth $809,000. Bank of New York Mellon Corp increased its position in Lantheus by 2.0% in the fourth quarter. Bank of New York Mellon Corp now owns 451,564 shares of the medical equipment provider’s stock worth $7,067,000 after buying an additional 9,033 shares during the period. Rhumbline Advisers increased its position in Lantheus by 1.0% in the first quarter. Rhumbline Advisers now owns 107,288 shares of the medical equipment provider’s stock worth $2,626,000 after buying an additional 1,097 shares during the period. Finally, California Public Employees Retirement System increased its position in Lantheus by 8.4% in the first quarter. California Public Employees Retirement System now owns 72,927 shares of the medical equipment provider’s stock worth $1,785,000 after buying an additional 5,669 shares during the period. 92.55% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts recently issued reports on LNTH shares. Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. BidaskClub lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $23.33.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: What are the economic characteristics of a bear market?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.